Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study

CONCLUSION: Treatment with sofosbuvir-velpatasvir or sofosbuvir-velpatasvir-voxilaprevir was safe and resulted in high SVR12 rates in Korean HCV patients.PMID:37424500 | PMC:PMC10338242 | DOI:10.3904/kjim.2022.252

Source: The Korean Journal of Internal Medicine - July 10, 2023 Category: Internal Medicine Authors: Jeong Heo Yoon Jun Kim Sung Wook Lee Youn-Jae Lee Ki Tae Yoon Kwan Soo Byun Yong Jin Jung Won Young Tak Sook-Hyang Jeong Kyung Min Kwon Vithika Suri Peiwen Wu Byoung Kuk Jang Byung Seok Lee Ju-Yeon Cho Jeong Won Jang Soo Hyun Yang Seung Woon Paik Hyung Jo Source Type: research